AARTI INDUSTRIES LTD. - 524208 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to state that the Earnings Call for Investors and Analysts has been scheduled on Monday, June 15, 2020 at 4:00 p.m. to discuss the Business Update of the Company. Please find attached herewith invitation for the same. AARTI INDUSTRIES LTD. - 524208 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Regulation 30 of the SEBI (LODR) Regulations, 2015 AARTI INDUSTRIES LTD. - 524208 - Intimation Under Regulation 31A Of The SEBI (LODR), (Sixth Amendment) Regulations, 2018.
In accordance with Regulation 31A of SEBI (LODR), (Sixth Amendment) Regulations, 2018, the Extract of the minutes of the meeting of the Board of Directors approving the request for Re-classification of shares is attached herewith.
Hold Aarti Industries; target of Rs 1002: East India Securities
East India Securities recommended hold rating on Aarti Industries with a target price of Rs 1002 in its research report dated May 29, 2020.
Accumulate Aarti Industries; target of Rs 992: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Aarti Industries with a target price of Rs 992 in its research report dated May 26, 2020.
Earnings Call Transcript - Q4FY20 for Aarti Industries
Conference Call with Aarti Industries Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full transcript. Management Commentary - Initial Remarks Call Participants: Mr. Rajendra Gogri - CMD, Mr. Rashesh Gogri - VC & MD, Mr. Chetan Gandhi - CFO Introductory Remarks from Rajendra Gogri Good evening and a very warm welcome to all of you. Firstly, I would like to wish that you remain in good health and stay safe in the current Covid-19 situation. I believe all of you would have received Q4 and FY20 in the financial result presentation that has been uploaded on the stock exchange website and emailed to you earlier today. The financial year ended March 31st, 2020 saw the business impact from various sectors including global economic weaknesses, slow demand in some large usage verticals, especially in agrochemicals, sharp volatility in the prices of key raw materials and currencies and finally the worldwide spread of the Covid-19 pandemic. Despite such exceptional business conditions, we have delivered revenues that are marginally lower by 3% and EBITDA was higher by 1.2%. EBITDA margin expanded by 80 basis points to 21.1%. Profit after tax increased by 8.9% to Rs 536 crore. During Q4 2020 operations of the company were disrupted about 10 days towards the end of the quarter due to the precautionary lockdown imposed by the government. There were restrictions on manpower movement and logistics and movement of goods for local supplies and exports. COVID-19 caused lower sales, higher inventory, production loss, etc. Topline to the extent of 9-10% was lower due to COVID-19, while the EBIT is impacted by about Rs 27-30 crores in the specialty chemical segment. This also resulted in some additional built up of inventory as on March 31, 2020. While we derived operating leverage from higher capacity utilization across key manufacturing locations, the commissioning of facilities for delivering on long-term supply contracts and the start of activities at the 4th R&D; centre in Q4 resulted in higher expenses and impacted profitability towards the end of the year. The benefits of these capabilities are long term in nature and will start to accrue progressively from FY21. In the specialty chemicals business, the weak raw material prices that are contractually passed on to customers saw revenues decline by about 3%. Operating profit, which we believe is the more important variable for evaluating our business, was almost unchanged at Rs 773 crore and EBIT margin expanded by 80 basis points to 21.1%. Underlying this was a visible shift in contribution from value-added chemistries that increased from 70% of revenues to over 75 % of revenues during the year. Production of some products was also constrained due to some issues related to the supply of nitric acid. On the production front, the production for nitrochlorobenzene was about 14,700 metric tonne for Q4 and 59,650 metric tonnes for FY20. In the pharma business, revenues increased by 4% while margins expanded by 250 basis points. Successful completion on USFDA Audits also testifies to our high standards of quality management, governance and compliance. Going forward, capacity expansions currently in the pipeline will drive deeper penetration in some key therapies such as antihypertensive, cardiovascular, oncology, corticosteriods, etc. We also have a strong pipeline of approvals and visibility to maintain our growth momentum. Overall, I would like to share with all of you that in our assessment, we have performed satisfactorily. We have made progress in expanding our manufacturing base, launched new products, continued to invest in R&D;/product/process development and believe that we are well-positioned to gain from the trend of global supply chains favourably looking at strong Indian chemical companies to establish long-term strategic supply arrangements. I would also like to share with you the impact related to the Covid-19 pandemic on the various aspects of the company’s business activities. The chemical manufacturing unit of the company had initially gone into temporary shutdown while the pharma business including essential goods continued manufacturing operations throughout this period. After securing supply chain logistics and mandatory compliance requirements, we resumed our operations at our manufacturing units during the first half of April. We are currently operating at 80% capacity utilization. Supply chain and labour availability challenges are being seen. The company is taking adequate efforts including revision and raise wherever applicable to secure the resources and mitigate the select. AARTI INDUSTRIES LTD. - 524208 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith the Q4 & FY20 Results Presentation of the Company for your records. AARTI INDUSTRIES LTD. - 524208 - Premature Repayment / Early Redemption Of 11.75 % Non-Convertible Debentures That Were Issued And Allotted On Private Placement Basis During The Financial Year 2014 -15
Board has Approved Premature Repayment / Early Redemption of Rs. 40 Crores, 11.75% Non-Convertible Debentures ('NCD') (ISIN:- INE769A07068). The Company has fixed/ approved: a) June 04, 2020 as the record date for the purpose of redemption of NCD along with the payment of such interest as may be due & b) June 10, 2020 as the date for redemption of NCD along with interest thereon.
